Lundbeckfonden Ventures co-led ocular cancer therapy developer Aura's series D round, which also featured Chiesi Ventures.
US-based oncology treatment developer Aura Biosciences closed a $40m series D round on Tuesday featuring Lundbeckfonden Ventures and Chiesi Ventures, corporate venturing vehicles for pharmaceutical firms Lundbeck and Chiesi Group.
Life sciences-focused investment firm Medicxi led the round, which also featured Arix Bioscience, Advent Life Sciences, Columbus Venture Partners, Ysios Capital and unspecified existing investors.
Founded in 2009, Aura Biosciences is working on a clinical-stage drug candidate called AU-011 to combat a rare and aggressive form of ocular cancer known…